乳腺癌患者血清脂联素检测的临床意义

目的:探讨乳腺癌患者血清脂联素含量的变化及其临床意义。方法:选择病理确诊的乳腺癌住院患者77例(转移者53例、未转移者24例)、对照组36例,术前抽取空腹静脉血并取血清,EL ISA法测定血清脂联素含量。结果:对照组血清脂联素含量7.29±2.06mg/L,乳腺癌未转移组血清脂联素含量4.51±1.98mg/L,乳腺癌转移组血清脂联素含量2.70±1.50mg/L,其含量逐渐下降(P<0.01)。乳腺癌患者TNM分期Ⅱ、Ⅲ、Ⅳ期血清脂联素含量依次为2.81±1.65mg/L,2.66±1.58mg/L,2.32±1.41mg/L,均低于Ⅰ期血清脂联素含量4.46±2.04mg/L(P<0.01),而Ⅱ、Ⅲ、Ⅳ期之间无显著性差异(P>0.05)。结论:乳腺癌患者血清脂联素含量降低,脂联素含量的降低程度在预测乳腺癌转移和预后方面具有指导意义。

The clinical significance of determination of adiponectin for the patients of breast cancer

Objective: To explore the clinical significance of determination of adiponectin for the patients of breast cancer .Methods: According to metastasis of carcinoma or not,77 patients of breast cancer who were diagnosed by pathology were divided into the metastasis group with 53 patients and the no-metastasis group with 24 patients,36 normal women were control group.The fasting venous blood was taken from all subjects.And Serum adiponectin concentrations was determined with enzyme linked immunosorbent assay(ELISA).Results: Serum adiponectin concentrations in the metastasis group(2.70±1.50mg/L) were lower than those in the no-metastasis group(4.51±1.98mg/L)(P<0.01),which were lower in the control group(7.29±2.06mg/L)(P<0.01).And Serum adiponectin in patients of TNM Ⅱ(2.81±1.65mg/L),Ⅲ(2.66±1.58 mg/L) and Ⅳ(2.32±1.41mg/L) stage of breast cancer were lower than that in patients of TNM Ⅰ(4.46±2.04mg/L)stage,but adiponectin concentrations showed not significant difference in patients of TNM Ⅱ,Ⅲ andⅣ stage(P>0.05).Conclusion: Serum adiponectin concentrations in patients of breast cancer were lower than in normal women,and the serum adiponectin stepping down may predict metastasis and prognosis of breast cancer.